MLNR (motilin receptor) is a G protein-coupled receptor located on chromosome 13 that binds motilin hormone and activates intracellular signaling pathways 1. The receptor functions as a transmembrane protein mediating hormone-receptor interactions at the plasma membrane with associated protein binding capabilities [GO annotations provided]. In terms of disease relevance, MLNR has been identified as a 'forerunner gene' whose silencing contributes to bladder carcinogenesis; specifically, MLNR downregulation dysregulates the basal-to-luminal urothelial differentiation program, sensitizing the urothelium to carcinogenic insults and promoting development of luminal-type bladder cancer 1. Loss of MLNR function represents an early alteration in field carcinogenesis, occurring before RB1 involvement in tumor development. Clinically, MLNR's role as a tumor suppressor in bladder cancer suggests potential therapeutic targeting of this pathway; however, its function in normal gastrointestinal physiology (motilin-mediated motility signaling) indicates that therapeutic strategies must carefully balance effects on both normal physiological function and cancer prevention. Additional clinical significance derives from MLNR's identification in bladder cancer molecular mapping studies, providing potential biomarker value for cancer risk stratification and early detection strategies in at-risk populations.